Search

Your search keyword '"Ding, Pei-Rong"' showing total 117 results

Search Constraints

Start Over You searched for: Author "Ding, Pei-Rong" Remove constraint Author: "Ding, Pei-Rong" Database Unpaywall Remove constraint Database: Unpaywall
117 results on '"Ding, Pei-Rong"'

Search Results

1. Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.

2. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study

3. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

4. Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial

5. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

6. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study

7. Efficacy of PD-1 inhibitors for Colorectal Cancer and Polyps in Lynch Syndrome Patients

12. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer

14. Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial

15. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer

16. Multi-omics analyses of single cell-derived colorectal cancer organoids reveal intratumor heterogeneity and immune response diversity

17. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study

18. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning

19. High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer

20. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer

21. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bm0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study

23. SONCAR study: A prospective randomized controlled study on optimized neoadjuvant chemotherapy-oxaliplatin plus CRT in patients with locally advanced rectal cancer.

24. A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study

25. Inflammatory Conditions Promote Resistance to Immune Checkpoint Inhibitors in High Microsatellite Instability Colorectal Cancer

26. Corrigendum to “Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer” [Canc. Lett. 500 (2021) 119-131]

27. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer

28. Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome

29. Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform

30. Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer

31. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer

32. Neoadjuvant Chemoradiotherapy in Patients With Unresectable Locally Advanced Sigmoid Colon Cancer: Clinical Feasibility and Outcome

33. Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel

34. Primary tumor immune score fails to predict the prognosis of colorectal cancer liver metastases after hepatectomy in Chinese populations

35. The watch-and-wait strategy versus surgical resection for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy

38. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer

39. Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy

40. Circulating tumor DNA as a promising biomarker of relapse risk for stage II-III colorectal cancer.

41. Low prevalence of mismatch repair deficiency in Chinese colorectal cancers: a multicenter study

42. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer

43. Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study

44. Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer

45. Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer

49. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors

Catalog

Books, media, physical & digital resources